Conference Track

Supportive Care

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Epoetin Alfa Improves Hematologic Outcomes in Women With Breast Cancer Receiving Dose-Dense Chemotherapy
Dexmethylphenidate Decreases Chemotherapy-Induced Fatigue and Memory Loss
Prochlorperazine Every 8 Hours Better Controls Delayed Emesis Than Patient-Administered Prochlorperazine or 5-HT₃ Receptor Antagonist Antiemetics
Aprepitant Plus 1-Day Ondansetron/Dexamethasone Superior to Multiday Ondansetron/Dexamethasone in Controlling Chemotherapy-Induced Nausea and Vomiting
Pegfilgrastim/Ciprofloxacin Provides Effective Support in Breast Cancer Patients Undergoing TAC Chemotherapy
Medroxyprogesterone More Effective Than Venlafaxine Against Hot Flashes in Breast Cancer Survivors
Epoetin Alfa More Effective Than Darbepoetin Alfa in Treatment of Chemotherapy-Related Anemia
Every-3-Week Epoetin Alfa Demonstrates Similar Efficacy, Toxicity, and Quality of Life as Standard Weekly Dosing Among Patients With Cancer-Associated Anemia
Venlafaxine Superior to Clonidine for Relief of Hot Flashes in Breast Cancer Patients
Pegfilgrastim Decreases Frequency of Neutropenia-Related Events vs Filgrastim in Clinical Practice
Febrile Neutropenia in Low-risk Patients Can Be Managed Safely in the Outpatient Setting
Prophylactic G-CSFs Reduce Febrile Neutropenia Risk and Infection-Related Mortality in Patients Receiving Chemotherapy
Pegfilgrastim Safe and Effective When Added to Myelosuppressive Chemotherapy
Comparable Results With Darbepoetin Alfa and Epoetin Alfa for Chemotherapy-Induced Anemia

Expert Analysis

Supportive Care

Program Director:
Roy A. Beveridge, MD

Faculty:
Joyce O’Shaughnessy, MD David H. Henry, MD Corey J. Langer, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss differences in patient response to different erythropoietic agents
Review data describing the impact of strategies for prophylaxis against febrile neutropenia and infection-related mortality
Describe studies comparing agents used to treat nausea and vomiting in patients with cancer

Earn CME credit by reading the expert analysis and commentary on supportive care. Topics covered include:

Epoetin Alfa and Hematologic Outcomes in High-Risk Breast Cancer
Epoetin Alfa Versus Darbepoetin Alfa
Comparison of Epoetin Alfa Dosing Schedules
Pegfilgrastim/Ciprofloxacin Prophylaxis
Meta-Analysis of Prophylactic Granulocyte Colony Stimulating Factors
Febrile Neutropenia in Low-Risk Patients, Outpatient Setting
Control of Delayed Nausea and Vomiting
Treatment of Hot Flashes in Breast Cancer
Dexmethylphenidate for Chemotherapy-Induced Fatigue and Memory Loss
Zoledronic Acid for Prevention of Treatment-Related Bone Loss

CME CREDIT INFORMATION

Release Date: 07/18/05

Expiration Date: 07/17/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.